glutathione capsule age limit Jarrow Formulas® Reduced Intracellular Antioxidant Capsules 500 mg, 60 ct S-Acetyl L-Glutathione 100 mg, 60

Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results

When to stop or modify protocols Discontinue or modify protocols if symptoms worsen progressively, if new neurological symptoms develop, if allergic reactions occur, or if significant side effects emerge

Gastrointestinal Support Some gastrointestinal side effects of NSAIDs may be addressed using gastroprotective nutrients (For more information, see Life Extensions Gastroesophageal Reflux Disease protocol)

Most brightening actives target the enzyme tyrosinase, which controls melanin formation